BMS, Pfizer, and AstraZeneca each made bold moves this week that signal how pharma is evolving. From deep direct-to-patient discounts and billion-dollar bets on obesity to a Supreme Court fight over Medicare pricing, the industry is rewriting its playbook. Access, affordability, and innovation are at the center of what comes next.

The week’s headlines reveal a pharma industry in motion — restructuring, retrenching, and doubling down where it counts. TruBio Consulting unpacks what these strategic pivots mean for leaders navigating market access, policy headwinds, and global competition.